

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s SYN045 tablets, a Type 1 new drug of chemical drug, has obtained approval from the National Medical Products Administration of China for adding three different specifications (10mg, 25mg and 50mg) for Phase I clinical trial, which can meet the diversified needs of clinical trials, achieve dose gradient for patients of different age groups, further optimize precise dosing regimen, and enhance the clinical application value of SYN045 tablets.

As stated in the Company’s announcement dated 8 November 2023, SYN045 is a highly selective PGI₂ receptor agonist. Currently, the Group’s preclinical studies have shown that SYN045 has good targeting selectivity, compound activity and safety, obvious anti-pulmonary hypertension effects on animals, and low toxicity which is favourable in achieving long-term oral administration. With the progression of the Phase I clinical trial of SYN045 tablets, the Group has entered the “fast lane” of Type 1 new drug.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 3 April 2025

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.